In conversation with... Steven Horwitz
from Listen to The Lancet Oncology Hosted by The Lancet
Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of Listen to The Lancet Oncology?
This episode is 15 minutes long.
When was this Listen to The Lancet Oncology episode published?
This episode was published on October 30, 2024.
Can I download this Listen to The Lancet Oncology episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.